LG Chem begins domestic sales of its first biosimilar
Published: 28 Jun. 2018, 19:28
The drug is a cheaper biosimilar of Amgen’s popular arthritis drug Enbrel (Etanercept).
The Korean company said it proved the efficacy and safety of the drug through a 52-week clinical trial on 370 patients in Korea and Japan that suffer from rheumatoid arthritis. It said there were significantly low adverse effects associated with the injection.
With the launch, the company hopes to expand its presence in the roughly 20 billion won ($17.7 million) arthritis treatment market in Korea.
The drug is available through an auto injector with slimmer needles, which helps patients inject the drug with more convenience and less pain.
By Kim Jee-hee
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)